Dendritic Cell-Based Vaccines for the Therapy of Experimental Tumors

Immunotherapy. 2010 Mar;2(2):257-68. doi: 10.2217/imt.10.7.

Abstract

Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells able to link the innate and adaptive immune systems. Many studies have focused on different immunotherapeutic approaches to applying DCs as tools to improve anticancer therapy. Although a number of investigations suggesting the benefit of DC-based vaccination during anticancer therapy have been reported, the general knowledge regarding the ultimate methods of DC-vaccine preparation is still unsatisfactory. In this article, the perspectives of DC-based anti-tumor immunotherapy and optimizing strategies of DC vaccination in humans in light of results obtained in mouse models are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antigen Presentation
  • Antigens, Neoplasm / immunology
  • Cancer Vaccines / therapeutic use*
  • Cell Differentiation
  • Cells, Cultured / immunology
  • Cells, Cultured / transplantation
  • Combined Modality Therapy
  • Cytokines / genetics
  • Dendritic Cells / cytology
  • Dendritic Cells / immunology*
  • Dendritic Cells / transplantation
  • Drug Screening Assays, Antitumor
  • Forecasting
  • Genetic Therapy
  • Genetic Vectors / therapeutic use
  • Immunotherapy, Active*
  • Injections, Intradermal
  • Injections, Intralymphatic
  • Injections, Subcutaneous
  • Mice
  • Mice, Inbred Strains
  • Neoplasms, Experimental / immunology
  • Neoplasms, Experimental / therapy*
  • Organ Specificity
  • Vaccination

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Cytokines